Navigation Links
Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
Date:3/10/2008

00 U/kg (30 mg/kg) were well-tolerated following either IV or SC

dosing.

-- Daily administration of rHuPH20 for one week was well tolerated via

either IV or SC delivery at a daily bolus dose of 600,000 U/kg

(5 mg/kg). No test article-related changes were observed in any

toxicology parameters and no systemic enzyme accumulation was observed.

-- A 3-month interim analysis from an ongoing 39-week chronic toxicity

study with weekly dosing up to 240,000 U/kg revealed no changes in

standard toxicity parameters or in male fertility assessment.

"These studies further expand the safety database for rHuPH20 in both dose and duration, and support the potential use of rHuPH20 from Halozyme's new manufacturing process in chronic applications," said Walter Bee, PhD, Halozyme's Vice President of Preclinical Development. "We anticipate that this toxicology package will be supportive of our current and future Enhanze(TM) Technology partners' regulatory applications."

About Enhanze Technology

Enhanze Technology is Halozyme's proprietary drug delivery technology based on recombinant human hyaluronidase (rHuPH20), a recombinant form of the naturally occurring human enzyme being investigated for its ability to break down hyaluronic acid (HA), the space-filling "gel"-like substance that is a major component of tissues throughout the body. When combined or co-formulated with certain injectable drugs, Enhanze(TM) Technology can act as a "molecular machete" to facilitate the penetration and dispersion of these drugs by temporarily opening flow channels under the skin. Molecules as large as 200 nanometers may pass freely through the perforated extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
2. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
3. Halozyme Therapeutics Amends Stockholder Rights Plan
4. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
5. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
6. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
7. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
8. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
9. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
11. ExonHit Therapeutics - 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Colo. , Aug. 26, 2014   Loveland ... global provider of high-performance crop input products and ... announced that the company has acquired a controlling ... -area agricultural biotechnology company delivering biochemical-based products for ... of Loveland Products, fastest growing plant nutrition brands, ...
(Date:8/26/2014)... 2014 Albany Molecular Research Inc. (NASDAQ: ... Marth , President and Chief Executive Officer at AMRI, ... on Monday, September 8, 2014 at 8:45 a.m. ET. ... presentation can be accessed at AMRI,s Investor Relations web ... will be archived for 90 days following the live ...
(Date:8/26/2014)... MA (PRWEB) August 26, 2014 ... solutions, today announced the release of Transform for ... for Electronic Data Capture (EDC) product line. It ... XClinical, and allows integration with MARVIN, the EDC ... as reducing study setup time, by allowing instantaneous ...
(Date:8/26/2014)... Spartan Bioscience today announced the ... Business Development. Mr. Shah is responsible for expanding ... in the United States and international markets. ... and strategic initiatives for the company’s rapid sample-to-result ... Shah was the Global Marketing Product Manager for ...
Breaking Biology Technology:Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 2Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 3Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 4Introducing Transform for MARVIN: Providing Further Flexibility for CROs and Sponsors in Partnership with XClinical 2Spartan Bioscience Names Charudutt Shah as Director of Business Development 2
... Behring, a world leader in the development of plasma-derived and ... CSL Behring – Prof. Heimburger Award 2011 . The ... this year,s theme to " Be Inspired, Get Involved in ... – Prof. Heimburger Award has been inspiring young medical ...
... SAN DIEGO, April 14, 2011 Promising new devices ... or heart failure, and related research, will be revealed ... Lung Transplantation (ISHLT) 31st Annual Meeting and Scientific Sessions. ... Neonates (PumpKIN) Program will be presented during the Meeting ...
... WORTH, Texas, April 14, 2011 The Wound Institute ... on dynamic reciprocity at the combined meeting of the ... Healing Society (WHS) being held in Dallas at the ... 2011. Presenting faculty are Dr. Ira M. Herman, tenured ...
Cached Biology Technology:CSL Behring Marks World Hemophilia Day by Announcing the Winners of the 'CSL Behring - Prof. Heimburger Award 2011' 2CSL Behring Marks World Hemophilia Day by Announcing the Winners of the 'CSL Behring - Prof. Heimburger Award 2011' 3CSL Behring Marks World Hemophilia Day by Announcing the Winners of the 'CSL Behring - Prof. Heimburger Award 2011' 4Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 2Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 3The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 2The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 3The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 4
(Date:8/25/2014)... battery-powered DNA diagnostic device invented at New Zealand,s ... commonly used field tool for rapidly detecting suspected ... the level of infection. , The breakthrough device, ... Queenstown Molecular Biology main meeting. It takes advantage ... target DNA sequences in real-time, without the need ...
(Date:8/25/2014)... of proteins that promotes virus entry into cells also ... and other viruses, University of Missouri researchers have found. ... insights into our understanding of not only HIV infection, ... Shan-Lu Liu, M.D., Ph.D., associate professor in the MU ... , The study was recently published in the ...
(Date:8/25/2014)... gentle and efficient cell separation from a device the ... to tilt-angle standing surface acoustic waves, according to a ... to do cell separation before analysis," said Tony Jun ... the separation process affects the integrity of the cells, ... work well.", Tilted-angle standing surface acoustic waves can separate ...
Breaking Biology News(10 mins):Revolutionary handheld DNA diagnostic unit allows lab-quality analysis in the field 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3Tilted acoustic tweezers separate cells gently 2
... 25, 2013   GenoVive , an innovator in personalized ... emerging "globesity" epidemic through its development of a state ... individual,s unique metabolism.  "Weight Loss Designed by Science" has ... an all natural meal and exercise program to assist ...
... After helping the US develop the atomic bomb, Niels ... was freely accessible. His thoughts remain highly relevant in ... of drones and space weapons in warfare raise questions ... consequences of technology. As part of the celebrations ...
... announced the release of a comprehensive, quality-controlled dataset that ... data on the massive Deepwater Horizon Oil Spill. The dataset, ... of dispersants, wraps up a three year process that began ... in the Gulf of Mexico during and after the oil ...
Cached Biology News:"GenoVive is changing the face of personalized health by continuing research efforts with Harvard." 2International Niels Bohr Conference: An open world 2NOAA launches website holding millions of chemical analyses from Deepwater Horizon oil spill 2
...
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
Biology Products: